Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Biogen is a global biotechnology company focused on neuroscience therapies, with core franchises in multiple sclerosis (Tecfidera, Tysabri, Vumerity) and spinal muscular atrophy (Spinraza). The company's stock is driven by MS product erosion from biosimilar competition, Alzheimer's drug Leqembi uptake trajectory, and pipeline execution in neuropsychiatry and rare diseases.
Biogen generates revenue through proprietary branded biologics with patent protection, commanding premium pricing ($80,000-$300,000+ annual treatment costs) in neurology markets with limited competition. Pricing power derives from clinical differentiation, high switching costs for stable patients, and specialty distribution through limited pharmacy networks. Gross margins exceed 70% due to biologic manufacturing scale, but operating leverage is constrained by 25-30% R&D reinvestment rates and high commercial infrastructure costs for specialty sales forces targeting neurologists.
Leqembi commercial uptake metrics - quarterly patient starts, infusion center capacity expansion, CMS reimbursement coverage decisions
MS franchise erosion rate - Tecfidera biosimilar market share loss, Tysabri patient retention, Vumerity formulary positioning
Pipeline readouts - Phase 3 data for neuropsychiatry assets (zuranolone depression), rare disease programs, and Alzheimer's tau antibody gosuranemab
Margin trajectory and capital allocation - cost reduction execution, share repurchase activity, business development deals
Biosimilar erosion of legacy MS franchise - Tecfidera facing generic competition, Tysabri patent expiries create structural revenue decline requiring pipeline replacement
Regulatory and reimbursement uncertainty for Alzheimer's therapies - CMS coverage restrictions, amyloid hypothesis validation debates, safety monitoring requirements limiting addressable market
Pricing pressure from government negotiation - IRA Medicare drug price negotiation could target high-cost biologics, European reference pricing compression
Leqembi competitive positioning versus Eli Lilly's donanemab (potentially superior efficacy/safety profile) and oral amyloid therapies in development
MS market share loss to Novartis Kesimpta, Roche Ocrevus, and next-generation BTK inhibitors with improved safety profiles
SMA market erosion as Novartis Zolgensma one-time gene therapy and Roche Evrysdi oral therapy gain share versus Spinraza intrathecal injections
Pipeline execution risk - limited late-stage assets beyond Leqembi create dependency on early-stage neuroscience programs with binary outcomes
Capital allocation pressure - declining cash flow from MS erosion may force choice between dividend sustainability, buybacks, and M&A investments
low - Biologic therapies for chronic neurological conditions exhibit minimal GDP sensitivity due to medical necessity, insurance coverage, and patient switching costs. Demand is clinically driven rather than economically driven, though severe recessions could pressure payer reimbursement rates and delay elective Alzheimer's diagnoses.
Rising rates create moderate valuation headwinds as biotech stocks trade on long-duration cash flows from pipeline assets 5-10 years out, compressing NPV of development programs. However, Biogen's established product portfolio and $2.1B free cash flow generation provide downside support versus pre-revenue biotechs. Higher rates also reduce M&A deal valuations, potentially creating inorganic growth opportunities.
minimal - Biogen maintains investment-grade credit profile with 0.38x debt/equity and $2.2B operating cash flow supporting debt service. Business model does not depend on credit availability for customers, though hospital/infusion center capital constraints could marginally slow Leqembi infrastructure buildout.
value - Stock trades at 2.9x sales and 10.6x EV/EBITDA, below biotech peer averages, attracting value investors betting on Leqembi inflection offsetting MS decline. 7.1% FCF yield appeals to income-oriented funds. Recent 41.9% one-year return reflects momentum from Leqembi approval, but base business deterioration creates ongoing value debate.
high - Biotech sector exhibits elevated volatility from binary clinical trial outcomes, FDA regulatory decisions, and reimbursement policy changes. Biogen beta historically 1.2-1.4x market, with stock prone to 10-20% single-day moves on pipeline readouts or competitive developments in Alzheimer's space.
